

Marketing on Hold for Medicare Advantage Plans

BY MARY ELLEN SCHNEIDER
New York Bureau

Several Medicare Advantage fee-for-service plan sponsors have agreed to voluntarily suspend marketing of their plans until officials at the Centers for Medicare and Medicaid Services can verify that they are in compliance with certain management controls.

CMS officials announced this temporary marketing moratorium as part of an

effort to halt deceptive marketing practices in the private fee-for-service Medicare market.

"It is our strong belief that while most agents and brokers are helpful and responsible in describing and explaining choices to beneficiaries, there are a few bad actors operating in the marketplace that need to be removed from the system," Abby Block, director of the Center for Beneficiary Choices at the CMS, said during a press briefing. "This voluntary agree-

ment demonstrates that the plans are stepping up to ensure that deceptive marketing practices end and that beneficiaries fully understand what they are purchasing."

From last December through April, CMS officials received about 2,700 complaints from beneficiaries regarding Medicare Advantage plans, with many of those complaints relating to private fee-for-service plans. However, Ms. Block pointed out that the 2,700 complaints account for a small fraction of the 1.3 mil-

lion Medicare beneficiaries who have elected to enroll in such plans.

The problems reported range from agents encouraging the misperception that the private plans are just like traditional Medicare and are accepted by all providers who accept Medicare to more blatant cases of deception in which agents have told beneficiaries they are still enrolled in traditional Medicare and are purchasing a Medigap supplemental insurance policy.

The seven private fee-for-service Medicare plans that recently signed an agreement with the CMS to suspend their marketing efforts are: United Healthcare, Humana, WellCare, Universal American Financial Corporation (Pyramid), Coventry, Sterling, and Blue Cross Blue Shield of

Tennessee. Together, they account for about 90% of enrollment in private fee-for-service plans, according to the CMS. "These are clearly the major players in the industry," Ms. Block said.

The plans were not singled out because of particular problems with their marketing practices, Ms. Block said. The real concern relates to actions by a small number of rogue brokers and agents with whom these and other organizations may contract, she said.

The temporary moratorium does not apply to enrollment among the plans and does not affect the employer market, where CMS has not received complaints of issues with marketing tactics.

The marketing moratorium will be lifted on a plan-by-plan basis when the CMS certifies that the plan has both systems and management controls in place that meet conditions spelled out by the agency in guidance earlier this year.

For example, plan sponsors will have to show that all of their advertising, marketing, and enrollment materials include model disclaimer language provided by the CMS that private fee-for-service Medicare plans are not the same as traditional Medicare or Medigap and that not all providers will accept the plan. All representatives selling products on behalf of a plan sponsor will have to pass a written test demonstrating familiarity with Medicare and fee-for-service plans.

Plans must also agree to provide a list of individuals who are marketing the plan upon request by the CMS or state agencies. The CMS will begin to review plans as soon as they indicate they are in compliance, Ms. Block said.

In addition, the CMS will be monitoring all private fee-for-service plans to ensure they are not engaging in deceptive marketing practices. "We will be watching very carefully as the entire industry begins marketing in October for the 2008 benefit year," Ms. Block said. ■

REGISTER TODAY FOR THIS EXCITING CME PROGRAM!



THE VENETIAN RESORT & CASINO

SKIN DISEASE EDUCATION FOUNDATION presents

THE 8TH ANNUAL

Las Vegas DERMATOLOGY SEMINAR™

A CONTINUING MEDICAL EDUCATION CONFERENCE

NOVEMBER 8-11, 2007

18 AMA PRA
Category 1 Credits™
Available

SCIENTIFIC PROGRAM

Featuring:

Two-part joint session with the International Society of Dermatology presenting global perspectives of today's dermatology

Leprosy - Current Status

Coccidioidomycosis - Diagnosis and Therapy

Mini-symposium on sclerosing cutaneous syndromes

Community Acquired MRSA Infections - Dermatologic Implications

Pharmacogenetics and the Dermatologist

Management of Non-melanoma Skin Cancer in Immunosuppressed Patients

Two-part Resident's Forum: Practical Management of Psoriasis

Stem Cells in Dermatology - What This Means for the Future

Modern Concepts in the Treatment of Seborrheic Dermatitis

Surgical and Cosmetic Update including Long Lasting Fillers, Botulinum Toxins and Selecting the Best Laser for Facial Rejuvenation

For more program information or to register, visit www.sdefderm.com or call 312.988.7700.

SEMINAR FACULTY

Meeting Directors:

Francisco A. Kerdel, MD
University of Miami, FL

Torello Lotti, MD*
University of Florence, Florence, Italy
*Friday and Saturday Joint Sessions Only

Sigfrid A. Muller, MD
University of Nevada, Las Vegas, NV

Faculty:

Hilary E. Baldwin, MD
SUNY, Brooklyn, NY

Ashish C. Bhatia, MD
Northwestern University, Chicago, IL

Janis E. Blair, MD
Mayo Clinic, Scottsdale, AZ

Suzanne Connolly, MD
Mayo Clinic, Scottsdale, AZ

Mark D.P. Davis, MD
Mayo Clinic, Rochester, MN

Senait W. Dyson, MD
University of California, Irvine, CA

Rokea el-Azhary, MD, PhD
Mayo Clinic, Rochester, MN

Joseph Fowler, Jr., MD
University of Louisville, Louisville, KY

Ruby Ghadially, MBChB, FRCPC
University of California, San Francisco, CA

Lawrence E. Gibson, MD
Mayo Clinic, Rochester, MN

Kenneth B. Gordon, MD
Northwestern University,
Feinberg School of Medicine, Chicago, IL

Joan Guitart, MD
Northwestern University,
Feinberg School of Medicine, Chicago, IL

Jana Hercogova, MD, PhD
Charles University, Prague, Czech Republic

Whitney High, MD
University of Colorado Medical School
Denver, CO

Robert E. Kalb, MD
SUNY at Buffalo School of Medicine
Buffalo, NY

Margaret Mann, MD
Washington University, School of Medicine
St. Louis, MO

David A. Mehregan, MD
Monroe, MI

Mark R. Pittelkow, MD
Mayo Clinic, Rochester, MN

George T. Reizner, MD
University of Wisconsin, Madison, WI

Glenn D. Roberts, PhD
Mayo Clinic, Rochester, MN

Henry H. Roenigk, Jr., MD
Scottsdale, AZ

Paolo Romanelli, MD
University of Miami, Hollywood, FL

Marimar Saez-de-Ocariz, MD
Instituto Nacional de Pediatría
Mexico City, Mexico

Janellen Smith, MD
University of California, Irvine, CA

Mary C. Spellman, MD
San Diego, CA

Thomas Stasko, MD
Vanderbilt University, Nashville, TN

Oliverio L. Welsh, MD, Dr Sc
Monterrey CP, Mexico

Stephen E. Wolverson, MD
Indiana University, Indianapolis, IN

James Yiannias, MD
Mayo Clinic, Scottsdale, AZ

Christopher B. Zachary, MBBS, FRCP
University of California, Irvine, CA

This activity is supported by educational grants from:

Barrier Therapeutics, Inc.

Centocor

Dermik Aesthetics

Johnson & Johnson

Consumer Products Company

OrthoNeutrogena

Ranbaxy Laboratories, Inc.

Stiefel Laboratories

Through The Lens, Inc.

The opinions expressed at Skin Disease Education Foundation seminars do not necessarily reflect those of Skin Disease Education Foundation, Elsevier Inc., or the supporters of the seminars. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in presentations, including any claims related to the products, drugs, or services mentioned.



SKIN DISEASE
EDUCATION
FOUNDATION
an Elsevier business

Jointly sponsored by